Key protein flattens with one-time chronic hepatitis B treatment
Chroma Medicine’s investigational one-time treatment CRMA-1001 for chronic hepatitis B brought levels of a key hepatitis B virus (HBV) protein to nearly 0 in…
Chroma Medicine’s investigational one-time treatment CRMA-1001 for chronic hepatitis B brought levels of a key hepatitis B virus (HBV) protein to nearly 0 in…
A U.S. Food and Drug Administration (FDA) advisory committee voted 10-1 that Ocaliva (obeticholic acid) doesn’t have a benefit-risk profile that would support its…
A new ABCB4 gene mutation was the likely cause of progressive familial intrahepatic cholestasis type 3 (PFIC3) in two unrelated Southeast Asian girls, a study…
A study showed that a genetic mutation associated with metabolic dysfunction-associated steatotic liver disease (MASLD), a form of fatty liver disease, results in an…
The American Liver Foundation (ALF) is granting its Spirit of Giving Family Award to a U.S. family for its dedication to raising funds and…
Researchers have uncovered the structure of the protein complex that allows the hepatitis C virus (HCV) to infect human cells, allowing them to reproduce and…
Advanz Pharma has secured a temporary suspension of a decision by the European Commission (EC) to revoke conditional approval of Ocaliva (obeticholic acid) for…
Scientists in Thailand have identified four new mutations in the PLEC gene as the likely cause of progressive familial intrahepatic cholestasis (PFIC) in two…
The Fatty Liver Alliance, a Canada-based advocacy group, is calling for supporters to sign a petition asking Madrigal Pharmaceuticals to apply to Canadian…
Cholestasis, where the flow of the digestive fluid bile from the liver to the intestines slows or stalls, is the most common feature across…